# Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction

> **NCT04731155** · PHASE4 · RECRUITING · sponsor: **Shanghai Tong Ren Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Early PCSK9 Inhibitor on Ventricular Remodling

## Interventions

- **DRUG:** PCSK9 inhibitor （Alirocumab）plus standard medications
- **DRUG:** standard medications

## Key facts

- **NCT ID:** NCT04731155
- **Lead sponsor:** Shanghai Tong Ren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-12
- **Primary completion:** 2025-10
- **Final completion:** 2025-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04731155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04731155, "Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04731155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*